Suppr超能文献

中医药成功治疗重组新型冠状病毒疫苗接种后亚急性甲状腺炎:一例报告

Successful Treatment of Subacute Thyroiditis After Recombinant COVID-19 Vaccination Using Traditional Chinese Medicine: A Case Report.

作者信息

Zhao Yong, Zhao Bo, Liang Ying Bing

机构信息

Respiratory Medicine, The Traditional Chinese Medicine Hospital of Lang fang City, LangFang City, CHN.

出版信息

Cureus. 2022 Oct 26;14(10):e30716. doi: 10.7759/cureus.30716. eCollection 2022 Oct.

Abstract

Subacute thyroiditis (SAT) is a thyroid inflammatory disease, which can be triggered by viral infection. The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is considered to be a potent SAT-triggering factor in this COVID-19 pandemic. However, SAT occurring after SARS-CoV-2 vaccination is rarely reported. Despite the high availability of diagnostic tools, the recurrence and steroid dependence as well as delayed diagnosis of SAT remain. This paper reports a rare case where a patient was diagnosed with SAT post receiving a recombinant novel coronavirus vaccine (Anhui Zhifei Longcom Biopharmaceutical Co.Ltd., China), and efficiently treated with traditional Chinese medicine rather than prednisone. We hope that this case report not only contributes to raising awareness of SAT related to the COVID-19 vaccine but also provides an effective remedy in addition to glucocorticoid (GC).

摘要

亚急性甲状腺炎(SAT)是一种甲状腺炎性疾病,可由病毒感染引发。在此次新冠疫情大流行中,严重急性呼吸综合征冠状病毒2(SARS-CoV-2)被认为是引发SAT的一个重要因素。然而,接种SARS-CoV-2疫苗后发生SAT的情况鲜有报道。尽管诊断工具应用广泛,但SAT的复发、对类固醇的依赖以及诊断延迟等问题依然存在。本文报告了一例罕见病例,一名患者在接种重组新型冠状病毒疫苗(中国安徽智飞龙科马生物制药有限公司生产)后被诊断为SAT,并采用中药而非泼尼松进行了有效治疗。我们希望本病例报告不仅有助于提高对与新冠疫苗相关的SAT的认识,还能在糖皮质激素(GC)之外提供一种有效的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d5e/9612889/7e6dabcde112/cureus-0014-00000030716-i01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验